公开(公告)号：KR1020100088749A

公开(公告)日：2010-08-11

申请号：KR1020090007836

申请日：2009-02-02

Applicant: 서울대학교산학협력단

Inventor： 정성근 ,  임태규 ,  최승환 ,  정명근 ,  이기원 ,  이형주

IPC: A61K36/254 ,  A61P17/00 ,  A23L1/30 ,  A61K31/70

CPC classification number: A61K36/254 ,  A23L2/52 ,  A23L29/035 ,  A23V2200/318 ,  A61K9/00 ,  A61K31/7048 ,  A61K2236/17 ,  A61K2236/30 ,  Y10S514/828

Abstract: PURPOSE: A pharmaceutical composition containing cyanidin-3-O-(2''-xylosyl) glucoside is provided to suppress COX-2 and the transcription factors such as AP-1 and NF-kappaB. CONSTITUTION: A pharmaceutical composition for preventing and treating dermatitis contains 0.1-50 weight% of Acanthopanax sessiliforium extract as an active ingredient. The Acanthopanax sessiliforium extract is obtained by drying Acanthopanax sessiliforium at 30-40°C for 44-52 hours, pulverizing, adding 50-99% of ethanol to the dried powder and extracting for 20-28 hours. The concentration of Acanthopanax sessiliforium is 10uM-1mM. The dermatitis includes skin cancer or skin inflammation.

Abstract translation: 目的：提供含有花青素-3-O-（2“ - 木糖基）葡萄糖苷的药物组合物，以抑制COX-2和转录因子如AP-1和NF-κB。 构成：用于预防和治疗皮炎的药物组合物含有0.1-50重量％的刺五加提取物作为活性成分。 刺五加提取物通过在30-40℃下干燥刺五加44-52小时，粉碎，向干粉中加入50-99％的乙醇并提取20-28小时得到。 刺五加浓度为10uM-1mM。 皮炎包括皮肤癌或皮肤炎症。